2[1]Pederson JR,Olsson AG,Faergeman V,et al.Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)[J].Circulation,1998,97:1453-1460.
3[2]Flaker GC,Warnica JW,Sacks FW,et al.For the Cholesterol and Recurrent Event (CARE) investigators.Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations[J].J Am Coll Cardiol,1999,34:106-112.
4[3]Downs JR,Clearfield M,Wies S,et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study[J].JAMA,1998,299:1615-1621.
5[4]Kinlay S.Early statin therapy in acute coronary syndromes[J].Minerva cardioangiol,2003,51(5):577-584.
6[5]Huggins GS,Pasternak PC,Alpert NM,et al.Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse[J].Circulation,1998,98:1291-1296.
7[6]Inoue T,Hayashi M,Takayanagi K,et al.Lipid-lowering therapy with fluvastain inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients[J].Atherosclerosis,2002,160(2):369-376.
8[7]Bybee KA,Wright RS,Kopecky SL.Effect of early statin therapy after acute coronary syndromes:a concise review of the recent data[J].Cardiol Rev,2002,10(5):301-305.
9[8]Mosca L,Biviano A.Lipid-lowering therapies in the management of acute coronary syndromes[J].Curr Cardiol Rep,2002,4(4):320-326.
10[9]Waters DD.Early pharmacologic intervention and plaque stability in acute coronary syndromes[J].Am J Cardiol,2001,88(8A):30K-36K.
